Over 90% of medications with preclinical activity fail in human trials, mainly because of insufficient efficacy. restorative candidates examined in humans possess preclinical activity however over 90% of the brokers fail during medical advancement (Kola and Landis, 2004; Ledford, 2011; Mak et al., 2014). This lamentable position quo results mainly from too little efficacy in… Continue reading Over 90% of medications with preclinical activity fail in human trials,